RecruitingPhase 1NCT06372821

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics

Sponsor

University College, London

Enrollment

10 participants

Start Date

Nov 18, 2024

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Summary

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.

Eligibility

Min Age: 21 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called NIO752, which is designed to reduce the production of tau — a protein that builds up harmfully in the brains of people with Alzheimer's disease. Researchers will measure how well the drug lowers tau levels using a specialized technique called SILK. **You may be eligible if...** - You are between 21 and 80 years old - You have mild or moderate Alzheimer's disease (Clinical Dementia Rating of 0.5 to 2) - Brain imaging or lab tests (CSF or blood biomarkers) support an Alzheimer's diagnosis - You are fluent in English and have a reliable caregiver or study partner **You may NOT be eligible if...** - You are not able to undergo lumbar punctures (spinal taps) or MRI scans - You have other neurological conditions explaining your symptoms - You are on blood thinners or other medications that conflict with the study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.